Mar 28, 2013, 12.06 PM IST | Source: Moneycontrol.com

Aurobindo Pharma jumps as FDA removes Unit VI import ban

Shares of Aurobindo Pharma surged more than 8 percent on Thursday after it said the US Food and Drug Administration has lifted the import alert for non-sterile products manufactured in its unit VI cephalosporin facility in Hyderabad, Andhra Pradesh.

Moneycontrol Bureau

Shares of Aurobindo Pharma surged more than 8 percent on Thursday after it said the US Food and Drug Administration has lifted the import alert for non-sterile products manufactured in its unit VI cephalosporin facility in Hyderabad, Andhra Pradesh.

This will pave the way for resuming exports of 9 products to the US market from the plant, the drug maker said.

The production facility that makes the anti-bacterial drug was audited by the USFDA in December 2010 and the drug regulator had issued an import alert in Feb 2011.

The unit had annual sales of USD 33 million prior to the import alert, Aurobindo said.

At 11:45 hrs, Aurobindo shares were up 8.9 percent at Rs 142.10 on NSE.

Aurobindo Pharm stock price

On April 17, 2014, Aurobindo Pharma closed at Rs 551.35, up Rs 3.35, or 0.61 percent. The 52-week high of the share was Rs 575.95 and the 52-week low was Rs 138.45.


The company's trailing 12-month (TTM) EPS was at Rs 31.05 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 17.76. The latest book value of the company is Rs 100.84 per share. At current value, the price-to-book value of the company is 5.47.

Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Rahul Gandhi

575.79 -0.44 -0.08%

54599

Bought today

50837

Sold today

0.21%

User holding

video of the day

Chandra says satisfied with TCS' FY14, FY15 to be better

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.